Microbiota-Driven Strategies for Managing IBD-Associated Risks: From Infections to Mental Health

TL;DR

This review explores how gut microbiota changes in IBD contribute to broader health issues and examines new microbiota-based treatments to improve patient outcomes.

Contribution

The paper introduces a framework for personalized IBD care focused on restoring microbiota homeostasis through novel microbiota-targeted strategies.

Findings

Microbiota disruptions in IBD are linked to systemic issues like infections and mental health problems.

FMT, LBPs, and precision postbiotics show promise as adjuncts to traditional IBD treatments.

Current barriers to microbiota-based therapies include safety concerns and microbiota heterogeneity.

Abstract

Inflammatory bowel diseases (IBD) are increasingly acknowledged not merely as confined gastrointestinal disorders but as systemic immunometabolic syndromes. Central to this paradigm is the gut microbiota including non-bacterial components such as the virome, whose functional disruption marked by reduced short-chain fatty acids (SCFAs), increasingly implicated in pathogenic processes extending beyond intestinal mucosa. This review outlines how these alternations compromise the epithelial barrier and immune regulation, increasing the risk of recurrent Clostridioides difficile infections to anemia, neuropsychiatric comorbidities, and extraintestinal manifestations. We critically evaluate emerging microbiota-targeted strategies, including fecal microbiota transplantation (FMT), live biotherapeutic products (LBPs), and precision postbiotics, positioning them as potential adjuncts to conventional immunosuppression. Finally, we discuss the current barriers to clinical translation, such as safety and heterogeneity, and propose a future framework for personalized, functionally integrated IBD care aimed at restoring long-term microbiota homeostasis.

Figures